Remdesivir (RDV)

DRUG3 trials

Sponsors

Gilead Sciences, Lebanese University, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Conditions

COVID - 19COVID-19Hospitalized COVID-19 PatientsRenal TransplantSARS CoV 2 Infection

Phase 1

Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

CompletedNCT04539262

Gilead SciencesCOVID-19

Start: 2020-09-14End: 2021-03-22Updated: 2022-03-03

LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients

RecruitingNCT05925140

Lebanese UniversityCOVID-19, Hospitalized COVID-19 Patients

Start: 2020-03-28End: 2025-12-30Target: 1000Updated: 2024-02-06

Phase 2

Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients

RecruitingNCT07197164

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaCOVID - 19, Renal Transplant, SARS CoV 2 Infection

Start: 2025-09-01End: 2027-02-28Target: 15Updated: 2025-09-29

Related Papers

Impact of <scp>COVID</scp>‐19 on the Conduct and Design of Clinical Trials: <scp>IQ</scp> Consortium Perspective

Clinical Pharmacology & Therapeutics2024-03-27